[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:myelodysplastic-syndrome":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":310,"states":367},"Myelodysplastic Syndrome",284,250,[8,16,22,28,35,41,47,53,60,66,72,78,85,91,96,102,107,112,118,124,130,136,142,148,154,160,166,172,178,184,190,196,202,208,214,220,226,232,238,244,250,257,263,268,274,280,286,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03874052","Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[12],"Phase 1","RECRUITING","2026-08-26T02:15:50.539717Z","2026-07-19T19:36:05.114969Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06492707","DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial",[12],"2026-08-03T00:57:52.718762Z","2026-07-05T05:32:16.757562Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06357182","Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia",[12],"2026-08-26T02:16:16.995720Z","2026-07-05T05:32:16.751844Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06847867","A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome",[32],"Phase 2","2026-08-26T02:15:10.362237Z","2026-07-05T05:32:16.701355Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07579429","Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)",[32],"2026-08-26T02:18:26.932189Z","2026-05-13T02:55:06.783013Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05703542","BXCL701 Phase 1 R\u002FR Acute Myeloid Leukemia or Myelodysplastic Syndrome",[12],"2026-08-26T02:18:35.425468Z","2026-05-05T02:43:29.711893Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07283094","FHD-286 With Low-Dose Weekly Decitabine\u002FVenetoclax in Patients With Acute Myeloid Leukemia",[12],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.674771Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT03173937","Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome",[57],"Phase 1\u002FPhase 2","2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.674573Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06616636","A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:29.528676Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05312255","Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma",[],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:29.474937Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07064122","A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)",[12],"2026-08-26T02:17:11.311767Z","2026-05-05T02:43:29.350818Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":83,"content_modified":84},"NCT06465953","Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation",[82],"Phase 3","2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.321717Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06445959","Phase 1b\u002F2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib",[57],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:29.294355Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":33,"content_modified":95},"NCT06419634","Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",[12],"2026-05-05T02:43:29.152384Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06303193","Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic\u002FMyeloproliferative Neoplasms",[57],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.140075Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":64,"content_modified":106},"NCT06996119","Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant",[12],"2026-05-05T02:43:29.070358Z",{"nct_id":108,"title":109,"phases":110,"status":13,"updated_at":51,"content_modified":111},"NCT06548230","A Phase 1B\u002F2A Trial of NADUNOLIMAB in Combination With Azacitidine (With\u002FWithout Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)",[57],"2026-05-05T02:43:29.069324Z",{"nct_id":113,"title":114,"phases":115,"status":13,"updated_at":116,"content_modified":117},"NCT04419649","A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)",[32],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:29.043989Z",{"nct_id":119,"title":120,"phases":121,"status":13,"updated_at":122,"content_modified":123},"NCT07096297","Luspatercept + Darbepoetin in MDS",[32],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:28.971039Z",{"nct_id":125,"title":126,"phases":127,"status":13,"updated_at":128,"content_modified":129},"NCT07422480","A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions",[82],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:28.870748Z",{"nct_id":131,"title":132,"phases":133,"status":13,"updated_at":134,"content_modified":135},"NCT03886662","A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)",[57],"2026-08-26T02:16:01.910993Z","2026-05-05T02:43:28.839152Z",{"nct_id":137,"title":138,"phases":139,"status":13,"updated_at":140,"content_modified":141},"NCT06641414","Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).",[82],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:28.812948Z",{"nct_id":143,"title":144,"phases":145,"status":13,"updated_at":146,"content_modified":147},"NCT06529731","Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation",[32],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:28.795399Z",{"nct_id":149,"title":150,"phases":151,"status":13,"updated_at":152,"content_modified":153},"NCT05308264","Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)",[57],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:28.716986Z",{"nct_id":155,"title":156,"phases":157,"status":13,"updated_at":158,"content_modified":159},"NCT05027945","A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome",[32],"2026-08-26T02:16:28.221034Z","2026-05-05T02:43:28.649636Z",{"nct_id":161,"title":162,"phases":163,"status":13,"updated_at":164,"content_modified":165},"NCT06969430","A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)",[57],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:28.558908Z",{"nct_id":167,"title":168,"phases":169,"status":13,"updated_at":170,"content_modified":171},"NCT06499285","A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions",[82],"2026-08-26T02:17:05.997056Z","2026-05-05T02:43:28.544797Z",{"nct_id":173,"title":174,"phases":175,"status":13,"updated_at":176,"content_modified":177},"NCT05483010","Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)",[32],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:28.543670Z",{"nct_id":179,"title":180,"phases":181,"status":13,"updated_at":182,"content_modified":183},"NCT00801489","Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[32],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.539567Z",{"nct_id":185,"title":186,"phases":187,"status":13,"updated_at":188,"content_modified":189},"NCT03816319","TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:28.536512Z",{"nct_id":191,"title":192,"phases":193,"status":13,"updated_at":194,"content_modified":195},"NCT01624805","Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and\u002For Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome",[32],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:28.419128Z",{"nct_id":197,"title":198,"phases":199,"status":13,"updated_at":200,"content_modified":201},"NCT04227847","A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies",[12],"2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.361282Z",{"nct_id":203,"title":204,"phases":205,"status":13,"updated_at":206,"content_modified":207},"NCT06399640","Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia",[12],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:28.339805Z",{"nct_id":209,"title":210,"phases":211,"status":13,"updated_at":212,"content_modified":213},"NCT03661307","Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",[57],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.288010Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":218,"content_modified":219},"NCT06577441","Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)",[32],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.989103Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT06680752","Clinical Study of ARD103 CAR-T Therapy for Patients With R\u002FR AML or MDS",[57],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:27.760562Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT06552416","Safety of MT-401-OTS in Patients With Relapsed AML or MDS",[12],"2026-08-26T02:17:06.985283Z","2026-05-05T02:43:27.669211Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT07107126","Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes",[12],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:27.644093Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT06297941","Study of REM-422 in Patients With AML or Higher Risk MDS",[12],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:27.627025Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT05986240","Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed\u002FRefractory MDS & AML",[12],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:27.486946Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":255,"content_modified":256},"NCT04187703","5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies",[254],"Early Phase 1","2026-08-26T02:19:29.922117Z","2026-05-05T02:43:27.320206Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT06498973","Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant",[12],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:27.316563Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":255,"content_modified":267},"NCT06656494","ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies",[12],"2026-05-05T02:43:27.283157Z",{"nct_id":269,"title":270,"phases":271,"status":13,"updated_at":272,"content_modified":273},"NCT06923488","Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes",[57],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:27.279905Z",{"nct_id":275,"title":276,"phases":277,"status":13,"updated_at":278,"content_modified":279},"NCT05211570","AB8939 in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[57],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:27.176406Z",{"nct_id":281,"title":282,"phases":283,"status":13,"updated_at":284,"content_modified":285},"NCT06146257","A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes",[12],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:27.108962Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT07508982","Phase1b\u002F2 Trial Of AZA + APG1252 In Patients With High-Risk AML",[57],"2026-08-26T02:19:01.741747Z","2026-05-05T02:43:27.099731Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT03896269","CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",[12],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:27.095227Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT01515527","Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)",[32],"2026-08-26T02:15:51.395565Z","2026-05-05T02:43:27.091217Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":308,"content_modified":309},"NCT04243785","A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[12],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:27.089277Z",[311,315,319,323,327,331,335,338,342,345,349,352,355,358,361,364],{"biomarker":312,"count":313,"slug":314},"HLA Complex",17,"hla-complex",{"biomarker":316,"count":317,"slug":318},"TP53 Gene",14,"tp53-gene",{"biomarker":320,"count":321,"slug":322},"Receptor-Type Tyrosine-Protein Kinase FLT3",12,"receptor-type-tyrosine-protein-kinase-flt3",{"biomarker":324,"count":325,"slug":326},"IDH1 Gene",11,"idh1-gene",{"biomarker":328,"count":329,"slug":330},"BCR\u002FABL1 Fusion Gene",9,"bcr-abl1-fusion-gene",{"biomarker":332,"count":333,"slug":334},"Interleukin-3 Receptor Subunit Alpha",7,"interleukin-3-receptor-subunit-alpha",{"biomarker":336,"count":333,"slug":337},"KMT2A Gene","kmt2a-gene",{"biomarker":339,"count":340,"slug":341},"HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain",5,"hla-class-i-histocompatibility-antigen-a-0201-alpha-chain",{"biomarker":343,"count":340,"slug":344},"IDH2 Gene","idh2-gene",{"biomarker":346,"count":347,"slug":348},"CD70 Antigen",3,"cd70-antigen",{"biomarker":350,"count":347,"slug":351},"EPO Gene","epo-gene",{"biomarker":353,"count":347,"slug":354},"HIV Infection","hiv-infection",{"biomarker":356,"count":347,"slug":357},"HLA-A Gene","hla-a-gene",{"biomarker":359,"count":347,"slug":360},"KERATIN 31, TYPE I","keratin-31-type-i",{"biomarker":362,"count":347,"slug":363},"MBD5 wt Allele","mbd5-wt-allele",{"biomarker":365,"count":347,"slug":366},"NPM1 Gene","npm1-gene",[368,372,376,380,384,388,392,396,400,404,407,411,415,419,423,427,431,435,438,442,446,450,453,457],{"state":369,"count":370,"slug":371},"Texas",96,"texas",{"state":373,"count":374,"slug":375},"California",74,"california",{"state":377,"count":378,"slug":379},"New York",72,"new-york",{"state":381,"count":382,"slug":383},"Florida",58,"florida",{"state":385,"count":386,"slug":387},"Ohio",47,"ohio",{"state":389,"count":390,"slug":391},"Massachusetts",44,"massachusetts",{"state":393,"count":394,"slug":395},"Maryland",42,"maryland",{"state":397,"count":398,"slug":399},"Pennsylvania",37,"pennsylvania",{"state":401,"count":402,"slug":403},"Illinois",34,"illinois",{"state":405,"count":402,"slug":406},"Tennessee","tennessee",{"state":408,"count":409,"slug":410},"North Carolina",33,"north-carolina",{"state":412,"count":413,"slug":414},"Washington",32,"washington",{"state":416,"count":417,"slug":418},"Georgia",28,"georgia",{"state":420,"count":421,"slug":422},"Missouri",27,"missouri",{"state":424,"count":425,"slug":426},"Michigan",24,"michigan",{"state":428,"count":429,"slug":430},"Oregon",23,"oregon",{"state":432,"count":433,"slug":434},"Minnesota",20,"minnesota",{"state":436,"count":433,"slug":437},"Wisconsin","wisconsin",{"state":439,"count":440,"slug":441},"New Jersey",19,"new-jersey",{"state":443,"count":444,"slug":445},"Colorado",18,"colorado",{"state":447,"count":448,"slug":449},"Alabama",16,"alabama",{"state":451,"count":448,"slug":452},"Connecticut","connecticut",{"state":454,"count":455,"slug":456},"Arizona",15,"arizona",{"state":458,"count":455,"slug":459},"Virginia","virginia"]